Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma

L. Claire Hollins, Paul Wirth, Gregory J. Fulchiero, Galen T. Foulke

Research output: Contribution to journalArticlepeer-review

Abstract

This case series discusses 3 patients with long-standing eczematous or psoriasiform dermatitis, demonstrated by multiple biopsies. Following off-label treatment with dupilumab, all 3 patients had clinical expansion of disease, with histopathologic features consistent with cutaneous T-cell lymphoma (CTCL) on subsequent biopsy. We postulate that this expansion likely was secondary to an exacerbation of extant CTCL following exposure to dupilumab. A proposed mechanism of promotion of CTCL is based on the functional increase in IL-13 available for binding at the upregulated IL-13 receptor (IL-13R) α2 site on cells, following blockade of the α1 receptor with dupilumab. This progression merits further investigation.

Original languageEnglish (US)
Pages (from-to)E8-E11
JournalCutis
Volume106
Issue number2
DOIs
StatePublished - Aug 1 2020

All Science Journal Classification (ASJC) codes

  • Dermatology

Fingerprint Dive into the research topics of 'Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma'. Together they form a unique fingerprint.

Cite this